Latest news with #pharmaindustry
Zawya
19-05-2025
- Business
- Zawya
Julphar plans to invest $81.7mln over next five years: CEO
Basel Ziyadeh, CEO of Gulf Pharmaceutical Industries (Julphar), affirmed that the company continues to strengthen its position as a key driver of the pharmaceutical industry in the UAE. He noted that Julphar exports more than 80% of its production to around 40 global markets, an achievement that reflects the advancement of its manufacturing infrastructure and the efficiency of national talent. In statements to the Emirates News Agency (WAM) on the sidelines of the first day of the 'Make it in the Emirates' forum, Ziyadeh revealed an ambitious investment plan worth AED300 million over the next five years. The plan aims to expand the manufacturing base and localise advanced technologies in cooperation with global partners, thereby supporting the national economy by boosting non-oil pharmaceutical exports. He explained that the company has invested about AED100 million over the past three years to enhance its manufacturing infrastructure and introduce new technologies. During the same period, it launched more than 35 new pharmaceutical products, meeting the needs of the local market and exporting to various countries. He stated that after more than 45 years since Julphar's establishment, the company proudly stands as one of the first pharmaceutical firms to launch from the UAE to the world, at a time when the Arab pharmaceutical industry was almost non-existent. Today, the company exports from the UAE to dozens of global markets, relying on one of the largest industrial bases in the Arab region.
Zawya
14-05-2025
- Business
- Zawya
Egypt: Rameda reports 44.3% YoY consolidated profit decline in Q1 2025
Arab Finance: The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) posted a 44.26% year-on-year (YoY) leap in consolidated net profits attributable to the parent company in the first quarter (Q1) of 2025, achieving EGP 82.243 million from EGP 57.009 million, according to a statement. However, revenues jumped to EGP 865.616 million in the January-March period, up from EGP 456.233 million in the corresponding period a year ago. Rameda's standalone net profits after tax rose to EGP 76.717 million in Q1 2025 from EGP 53.539 million in Q1 2024. Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals. It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others. © 2020-2023 Arab Finance For Information Technology. All Rights Reserved. Provided by SyndiGate Media Inc. (
Malay Mail
12-05-2025
- Business
- Malay Mail
Trump vows up to 80pc cut in US drug prices with ‘most favoured nation' order
WASHINGTON, May 12 — President Donald Trump unveiled plans Sunday for a new policy on pharmaceuticals he claimed would reduce US prescription drug prices by between 30 and 80 per cent. 'They will rise throughout the World in order to equalize and, for the first time in many years, bring FAIRNESS TO AMERICA!' Trump wrote in a social media post, adding he planned to sign an executive order bringing the new policy into effect at 9am (1300 GMT) on Monday. Trump said he planned to institute a 'MOST FAVORED NATION'S' policy that pinned the cost of drugs sold in the United States to the lowest price paid by other countries for the same drug. The reduction in prescription drug costs in the United States would, he added, be counterbalanced by higher costs in other countries. 'Most favored nation' status is a World Trade Organisation rule that aims to prevent discrimination between a country and its trading partners, levelling the playing field for international trade. The White House did not immediately respond to an AFP request for details of the plan. This is not the first time that Trump has attempted to lower US drug prices. During his first 2017-2021 term in office, he announced a similar proposal to cut US drug prices but his plans failed in the face of strong opposition from the pharmaceutical industry. Last month, the US president signed an executive order aiming to lower crippling drug prices by giving states more leeway to bargain-hunt abroad and improving the process for price negotiations. — AFP
Arab News
12-05-2025
- Health
- Arab News
Trump says will sign order aimed at cutting US drug prices
WASHINGTON: President Donald Trump unveiled plans Sunday for a new policy on pharmaceuticals he claimed would reduce US prescription drug prices by between 30 and 80 percent. 'They will rise throughout the World in order to equalize and, for the first time in many years, bring FAIRNESS TO AMERICA!' Trump wrote in a social media post, adding he planned to sign an executive order bringing the new policy into effect at 9:00 am (1300 GMT) on Monday. Trump said he planned to institute a 'MOST FAVORED NATION'S' policy that pinned the cost of drugs sold in the United States to the lowest price paid by other countries for the same drug. The reduction in prescription drug costs in the United States would, he added, be counterbalanced by higher costs in other countries. 'Most favored nation' status is a World Trade Organization rule that aims to prevent discrimination between a country and its trading partners, levelling the playing field for international trade. The White House did not immediately respond to an AFP request for details of the plan. This is not the first time that Trump has attempted to lower US drug prices. During his first 2017-2021 term in office, he announced a similar proposal to cut US drug prices but his plans failed in the face of strong opposition from the pharmaceutical industry. Last month, the US president signed an executive order aiming to lower crippling drug prices by giving states more leeway to bargain-hunt abroad and improving the process for price negotiations.
Bloomberg
08-05-2025
- Business
- Bloomberg
GOP Eyes Pharma Tax Hike, Nixing Drug Price Deal for Trump Bill
House Republicans are considering nixing a Medicaid drug pricing plan floated by President Donald Trump and fiercely opposed by the pharmaceutical industry as the party pushes to strike a massive tax and spending deal in the coming days. But drugmakers may not be totally off the hook.
